Abstract：Parkinson′s disease is a chronic progressive neurodegenerative disease. The main clinical manifestations include motor syptoms such as bradykinesia, tremor, rigidity, and postural instability, as well as non-motor symptoms, such as impaired olfaction, sleep disorder, cognitive impairment, and emotional disorder. Melatonin is a hormone synthesized mainly by the pineal gland, regulating the circadian rhythm. Besides it acts as a free-radical scavenger, with neuroprotective, anti-inflammatory, and antioxidant properties. The unbalance of pineal melatonin synthesis disposes the body to a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson′s disease. Parkinson′s disease is due to the impairment of melatonin concentration and the expression of its receptor in the brain. Exogenous melatonin treatment improves its motor symptoms. Besides, it also shows effects on non-motor symptoms, such as sleep disorders, congnitive disorders, anxiety and depression. The aim of this review is to summarize the knowledge about the potential role of the melatoninergic system in the pathogenesis and treatment of Parkinson′s disease.
胡莹莹 汪锡金. 帕金森病与褪黑素相关性的研究进展[J]. 中国医药导报, 2018, 15(21): 23-26.
HU Yingying WANG Xijin. Study advance in the relationship between Parkinson′s disease and melatonin. 中国医药导报, 2018, 15(21): 23-26.
[1] Fifel K，DeBoer T. The central clock in patients with Parkinson disease [J]. JAMA Neurol，2014，71（11）：1456-1457.
[2] Alghamdi BS. The neuroprotective role of melatonin in neurological disorders [J]. J Neurosci Res，96（7）：1136-1149.
[3] Hughes KC，Gao X，Kim IY，et al. Intake of dairy foods and risk of Parkinson disease [J]. Neurology，2017，89（1）：46-52.
[4] Noyce AJ，Bestwick JP，Silveira-Moriyama L，et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease [J]. Ann Neurol，2012，72（6）：893-901.
[5] Ma C，Liu Y，Neumann S，et al. Nicotine from cigarette smoking and diet and Parkinson disease：a review [J]. Transl Neurodegener，2017，6（1）：18.
[6] James A. Mortimer ARB，Nelson LM. Associations of welding and manganese exposure with Parkinson disease [J]. Neurology （ECronicon），2012，79（11）：1174-1180.
[7] Corti O，Lesage S，Brice A. What genetics tells us about the causes and mechanisms of Parkinson′s disease？ [J]. Physiol Rev，2011，91（4）：1161-1218.
[8] Ransohoff RM. How neuroinflammation contributes to neurodegeneration? [J]. Science，2016，353（6301）：777-783.
[9] Devoto VMP，Falzone TL. Mitochondrial dynamics in Parkinson′s disease：a role for α-synuclein?[J]. Dis Model Mech，2017，10（9）：1075.
[10] Pringsheim T，Jette N，Frolkis A，et al. The Prevalence of Parkinson′s Disease：A Systematic Review and Meta-analysis [J]. Mov Disord，2014，29（13）：1583-1590.
[11] O′Neal-Moffitt G，Delic V，Bradshaw PC，et al. Prophylactic melatonin significantly reduces Alzheimer′s neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPP（swe）/PS1 mice [J]. Mol Neurodegener，2015，10（1）：27-48.
[12] Ozsoy O，Yildirim FB，Ogut E，et al. Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model [J]. Free Radic Res，2015， 49（8）：1004-1014.
[13] Naskar A，Prabhakar V，Singh R，et al. Melatonin enhances L-DOPA therapeutic effects，helps to reduce its dose and protects dopaminergic neurons in MPTP-induced parkinsonism in mice [J]. J Pineal Res，2015，58（3）：262-274.
[14] Díaz-Casado ME，Lima E，García JA，et al. Melatonin rescues zebrafish embryos from the parkinsonian phenotype restoring the Parkin/PINK1/DJ-1/MUL1 network[J].J Pineal Res，2016，61（1）：96-107.
[15] Gutierrezvaldez AL，Anayamartínez V，Ordoñezlibrado JL，et al. Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats：dyskinesia，motor performance，and cytological analysis [J]. ISRN Neurol，2015，2012（3）：360-379.
[16] Zaitone SA，Hammad LN，Farag NE. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1，2，3，6-tetrahydropyridine-parkinsonian mice[J]. Pharmacol Rep，2013，65（5）：1213-1226.
[17] Medeiros CA，Pf CDB，Lopes LA，et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson′s disease. A randomized，double blind，placebo-controlled study [J]. J Neurol，2007，254（4）：459-464.
[18] Yildirim FB，Ozsoy O，Tanriover G，et al. Mechanism of the benefcial effect of melatonin in experimental Parkinson′s disease [J]. Neurochem Int，2014，79（52）：1-11.
[19] Bassani TB，Gradowski RW，Zaminelli T，et al. Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson′s disease model in rats [J]. Brain Res，2014，1593（1）：95-105.
[20] Willis GL，Armstrong SM. A therapeutic role for melatonin antagonism in experimental models of Parkinson′s disease [J]. Physiol Behav，1999，66（5）：785-795.
[21] Rutten S，Vriend C，van den Heuvel OA，et al. Bright Light Therapy in Parkinson's Disease：An Overview of the Background and Evidence [J]. Parkins Dis，2012，2012（4）：1-9.
[22] Mack JM，Schamne MG，Sampaio TB，et al. Melatoninergic System in Parkinson′s Disease：From Neuroprotection to the Management of Motor and Nonmotor Symptoms [J]. Oxid Med Cell Longev，2016，2016（10）：1-31.
[23] Duncan GW，Khoo TK YAJ，O'Brien JT CSY，et al. Health-related quality of life in early Parkinson's disease：the impact of nonmotor symptoms [J]. Mov Disord，2014，29（2）：195-202.
[24] Breen DP，Vuono R，Nawarathna U，et al. Sleep and circadian rhythm regulation in early Parkinson disease [J]. JAMA Neurol，2014，71（5）：589-595.
[25] Iranzo A.Sleep in neurodegenerative diseases [J]. Sleep Med Clin，2016，11（1）：1-18.
[26] Videnovic A，Noble C，Reid KJ，et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease [J]. JAMA Neurol，2014，71（4）：463-469.
[27] Tholfsen LK，Larsen JP，Schulz J，et al. Development of excessive daytime sleepiness in early Parkinson disease [J]. Neurology，2015，85（2）：162-168.
[28] Trotti LM，Bliwise DL. Treatment of the sleep disorders associated with Parkinson′s disease [J]. Neurotherapeutics，2014，11（1）：68-77.
[29] Jennum P，Christensen JA，Zoetmulder M. Neurophysiological basis of rapid eye movement sleep behavior disorder：informing future drug development [J]. Nat Sci Sleep， 2016，8（1）：107-120.
[30] Bassetti CL，Bargiotas P. REM Sleep Behavior Disorder [J]. Front Neurol Neurosci，2018，41：104-116.
[31] Ding W，Ding LJ，Li FF，et al. Neurodegeneration and cognition in Parkinson′s disease：a review [J]. Eur Rev Med Pharmacol Sci，2015，19（12）：2275-2281.
[32] Wang LM，Suthana NA，Chaudhury D，et al. Melatonin inhibits hippocampal long-term potentiation [J]. Eur J Neurosci，2010，22（9）：2231-2237.
[33] Datieva VK，Rosinskaia AV，Levin OS. The use of melatonin in the treatment of chronic fatigue syndrome and circadian rhythm disorders in Parkinson′s disease [J]. 2013，113（2）：77-81.
[34] Capitelli C，Sereniki A，Lima MM，et al. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats [J]. Eur J Pharmacol，2008，594（1-3）：101-108.
[35] Bassani TB，Gradowski RW，Zaminelli T，et al. Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats [J]. Brain Res，2014，1593（17）：95-105.
[36] Bolitho SJ，Naismith SL，Rajaratnam SM，et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease [J]. Sleep Med，2014，15（3）：342-347.
[37] Dissanayaka NN，White E，O'Sullivan JD，et al. The clinical spectrum of anxiety in Parkinson's disease [J]. Mov Disord，2014，29（8）：967-975.
[38] Datieva VK，Rosinskaia AV，Levin OS. The use of melatonin in the treatment of chronic fatigue syndrome and circadian rhythm disorders in Parkinson′s disease [J]. Zh Nevrol Psikhiatr Im S S Korsakova，2013，113（2）：77-81.
2018, Vol. 15 
京公网安备 11010502046598号